Study #2020-1281
NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IB?III NONSMALL CELL LUNG CANCER
MD Anderson Study Status
Enrolling
Treatment Agent
Alectinib, Chemotherapy, Entrectinib, Vemurafenib (Enrollment closed), Cobimetinib (Enrollment closed), Pralsetinib (Enrollment closed), Atezolizumab, SBRT, Divarasib
Description
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer
Study phase:
Phase II
Physician name:
Marcelo Vailati Negrao
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.